Skip to main content

Dyne Therapeutics

Dyne Therapeutics Inc is a clinical-stage biotechnology enterprise headquartered in Waltham, Massachusetts. The company specializes in the discovery and development of novel oligonucleotide therapeutics designed to treat genetically driven rare muscle diseases. Its proprietary FORCE platform leverages antibody-antigen interactions to deliver modern genetic medicines directly into muscle tissue, targeting conditions such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Principal revenue is currently earned through research grants, biopharmaceutical collaborations, and capital financing agreements. The enterprise serves patients suffering from debilitating neuromuscular disorders. Dyne Therapeutics Inc is publicly listed on the Nasdaq Stock Market.

8 of the funds FundTelligence covers report a position in Dyne Therapeutics.

Legal name
DYNE THERAPEUTICS INC
Sector
Health Care
Country
United States
Funds holding it
8
Exposure themes
Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics

Funds holding Dyne Therapeutics

Loading...